Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives $99.11 Average PT from Brokerages

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) has earned a consensus recommendation of “Moderate Buy” from the fifteen research firms that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell recommendation, twelve have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $104.40.

GPCR has been the topic of several recent analyst reports. Guggenheim raised their price target on Structure Therapeutics from $90.00 to $140.00 and gave the company a “buy” rating in a report on Tuesday. Wall Street Zen upgraded shares of Structure Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Wednesday, October 8th. Morgan Stanley raised their price objective on Structure Therapeutics from $120.00 to $125.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Finally, Jefferies Financial Group set a $125.00 target price on Structure Therapeutics and gave the stock a “buy” rating in a research note on Thursday, December 11th.

Structure Therapeutics Price Performance

NASDAQ GPCR opened at $93.79 on Monday. The company’s 50 day simple moving average is $58.68 and its two-hundred day simple moving average is $35.63. Structure Therapeutics has a 1 year low of $13.22 and a 1 year high of $94.90. The stock has a market capitalization of $5.69 billion, a PE ratio of -76.88 and a beta of -2.05.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.01). On average, research analysts anticipate that Structure Therapeutics will post -0.82 EPS for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of GPCR. State of Wyoming bought a new stake in Structure Therapeutics in the second quarter valued at approximately $28,000. EverSource Wealth Advisors LLC increased its stake in shares of Structure Therapeutics by 530.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock worth $30,000 after buying an additional 901 shares during the period. Assetmark Inc. raised its holdings in Structure Therapeutics by 39.9% during the 2nd quarter. Assetmark Inc. now owns 2,877 shares of the company’s stock valued at $60,000 after buying an additional 820 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in Structure Therapeutics by 29.1% during the 2nd quarter. PNC Financial Services Group Inc. now owns 4,415 shares of the company’s stock valued at $92,000 after buying an additional 994 shares during the period. Finally, ANTIPODES PARTNERS Ltd grew its holdings in Structure Therapeutics by 39.1% in the 3rd quarter. ANTIPODES PARTNERS Ltd now owns 4,078 shares of the company’s stock worth $114,000 after acquiring an additional 1,146 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.